Cost-Effectiveness in Bladder Cancer
This trial is active, not recruiting.
|Sponsor||Erasmus Medical Center|
|Collaborator||ZonMw: The Netherlands Organisation for Health Research and Development|
|Start date||July 2002|
|End date||July 2005|
|Trial size||500 participants|
|Trial identifier||NCT00126958, *ZON-MW 945-02-046*|
This randomized clinical multicentre trial aims to evaluate the efficacy of microsatellite analysis on voided urine to detect tumour recurrences in the follow-up of patients with superficial urothelialcell carcinoma (UCC). Further, this study aims to identify subgroups of patients with a low risk of tumour recurrence using clinico-pathologic tumour characteristics in combination with a genetic marker (FGFR3 gene), such that the frequency of follow-up contact can be reduced. The overall objective is to reduce the frequency of cystoscopy during follow-up in patients with superficial UCC, leading to an improvement in quality of life at equal or lower costs. This study evaluates the cost-effectiveness of follow-up in bladder cancer.
Male or female participants of any age.
Inclusion Criteria: - All patients with resectable pT1 or pTa, grade G1-G2 transitional cell carcinoma of the bladder which is biopsy proven Exclusion Criteria: - Patients who present or presented with a transitional cell carcinoma of the bladder, stage pT2 or more invasive, or carcinoma in situ (CIS) and/or G3 diagnosed in history
|Official title||Cost-Effectiveness of Follow-up of Patients With Superficial Bladder Cancer|
|Principal investigator||Th. van der Kwast, Prof PhD MD|
|Description||The randomized clinical study consists of two intervention arms. The control arm consists of a conventional follow-up based on regular monitoring for urinary bladder UCC recurrences by cystoscopy. In the test arm a proportion of the cystoscopies is replaced by microsatellite analysis on voided urine. Both arms will be stratified for clinical and pathological tumour parameters as well as for the mutation status of the prognostic FGFR3 gene mutation.|
Call for more information